^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:Jaypirca (pirtobrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    01/27/2023
    Excerpt:
    JAYPIRCA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inh bitor....This indication is approved under accelerated approval based on response rate.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/08/2023
    Excerpt:
    Mantle Cell Lymphoma….Pirtobrutinib (non-covalent BTKi) added as a category 2A recommendation